Common Medications Can Prolong Back Pain When Overused, Study Says
A clinical trial will be needed to verify the research, which offered a warning about taking steroids or nonprescription drugs for weeks on end. (Source: NYT Health)
Source: NYT Health - May 12, 2022 Category: Consumer Health News Authors: Gina Kolata Tags: Back (Human Body Part) Pain Chronic Condition (Health) Drugs (Pharmaceuticals) Mice Steroids Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Ibuprofen (Drug) Dexamethasone (Drug) Research Science Translational Medicine (Journal) your-f Source Type: news

Elotuzumab Combination Disappoints in Newly Diagnosed Myeloma
(MedPage Today) -- Adding the monoclonal antibody elotuzumab (Empliciti) to lenalidomide (Revlimid) and dexamethasone failed to improve outcomes for patients with newly diagnosed, transplant-ineligible multiple myeloma, a phase III trial showed... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 12, 2022 Category: Hematology Source Type: news

Dexamethasone Reduces Morphine Consumption After Total Knee Arthroplasty
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - April 21, 2022 Category: Orthopaedics Tags: CME Article Source Type: news

Novel Steroid Therapy May Counter Ataxia Telangiectasia Novel Steroid Therapy May Counter Ataxia Telangiectasia
A novel therapy for ataxia telangiectasia that delivers dexamethasone sodium phosphate through red blood cells is both ' promising and impressive ' in a new phase 3 trial, experts say.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 8, 2022 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news

U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Regimen
TITUSVILLE, N.J., March 29, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (cabotegravir and rilpivirine) for the treatment of HIV-1 in virologically suppressed adolescents (HIV-1 RNA less than 50 copies per milliliter [c/mL]) who are 12 years of age or older, weigh at least 35 kg and are on a stable antiretroviral regimen, with no history of treatment failure, nor known or suspected resistance to either cabotegravir or rilpivirine.1,2 Co-developed as part of a collaboration with ViiV Healthcare, CABENUVA is the first ...
Source: Johnson and Johnson - March 30, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

U.S. FDA Approves Streamlined Process for Initiating HIV Therapy with CABENUVA (cabotegravir and rilpivirine), the First and Only Complete Long-Acting Injectable HIV Treatment
TITUSVILLE, N.J., March 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved a label update for CABENUVA (cabotegravir and rilpivirine), giving healthcare professionals and people living with human immunodeficiency virus (HIV-1) in the U.S. the option to start this once-monthly or every-two-month injectable treatment without the need for the oral lead-in phase (daily cabotegravir and rilpivirine tablets, taken for one month prior to initiation of cabotegravir and rilpivirine injections).1 Clinical data demonstrated the regimen di...
Source: Johnson and Johnson - March 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

RECOVERY Trial shows baricitinib reduces deaths in COVID-19 hospitalised patients, NIHR
The NIHR-supported RECOVERY trial has found that baricitinib, an anti-inflammatory rheumatoid arthritis drug, reduces deaths in patients hospitalised for COVID-19 by around one-fifth. The benefit was in addition to those of dexamethasone and tocilizumab, two other anti-inflammatory treatments which have previously been shown to reduce the risk of death in these patients. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 17, 2022 Category: Consumer Health News Source Type: news

Continued Dexamethasone at Discharge Not Tied to Better COVID-19 Outcomes
WEDNESDAY, March 9, 2022 -- For individuals hospitalized with COVID-19, continuing treatment with dexamethasone at discharge is not associated with a reduction in 14-day all-cause readmission or mortality, according to a study published online March... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 9, 2022 Category: Pharmaceuticals Source Type: news

U.S. FDA Approves CABENUVA (rilpivirine and cabotegravir) for Use Every Two Months, Expanding the Label of the First and Only Long-Acting HIV Treatment
TITUSVILLE, N.J., February 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved an expanded label for CABENUVA (rilpivirine and cabotegravir) to be administered every two months for the treatment of HIV-1 in virologically suppressed adults (HIV-1 RNA less than 50 copies per milliliter [c/ml]) on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either rilpivirine or cabotegravir. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janss...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Reports Q4 and Full-Year 2021 Results
New Brunswick, N.J. (January 25, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2021. “Our 2021 performance reflects continued strength across all segments of our business. Guided by Our Credo, I am honored to assume the role of CEO, leading our global teams in continuing our work to deliver life-changing solutions to consumers, patients, and health care providers” said Joaquin Duato, Chief Executive Officer. “Given our strong results, financial profile, and innovative pipeline we are well positioned for success in 2022 and beyond.” OVERALL FINANCIAL RESULTS ...
Source: Johnson and Johnson - January 25, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news

COVID antiviral Molnupiravir to be tested in RECOVERY trial on hospitalised patients
The RECOVERY Trial was launched as an emergency response in March 2020 and has so far discovered three effective treatments for COVID-19 - the inexpensive steroid dexamethasone; the arthritis drug tocilizumab; and an artificial antibody treatment, now known as Ronapreve. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 24, 2022 Category: Pharmaceuticals Source Type: news

Dexamethasone Effective as an Analgesic Adjuvant in Total Knee Replacement Dexamethasone Effective as an Analgesic Adjuvant in Total Knee Replacement
Two doses of dexamethasone given in the perioperative period reduced morphine consumption during 48 hours after total knee arthroplasty in the randomized, placebo-controlled DEX-2-TKA trial.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - January 18, 2022 Category: Orthopaedics Tags: Anesthesiology News Source Type: news

Adding a SN Block to TKA When NSAIDs are Contraindicated Adding a SN Block to TKA When NSAIDs are Contraindicated
Might a low concentration of popliteal-sciatic nerve block and dexamethasone be an effective adjunct for early postoperative pain control in patients intolerant of NSAIDs?BMC Anesthesiology (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - January 11, 2022 Category: Orthopaedics Tags: Anesthesiology Journal Article Source Type: news

HiDex 6 day (Dexamethasone Tablets USP, 1.5 mg) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 21, 2021 Category: Drugs & Pharmacology Source Type: news

New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
The objective responsive rate observed in this study suggests a potential benefit for many patients with triple-class exposed disease with an off-the-shelf therapy.”As of September 2021, 165 patients were treated with teclistamab at the SC 1.5 mg/kg dose across both Phase 1 and Phase 2 of MajesTEC-1.1 The primary objectives of the MajesTEC-1 Phase 1 study (NCT03145181) were to identify the recommended SC RP2D (part 1) and characterize the safety and tolerability of teclistamab at the RP2D (part 2). The primary objective of the MajesTEC-1 Phase 2 study (NCT04557098) was to evaluate the efficacy of teclistamab at the RP2D,...
Source: Johnson and Johnson - December 13, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news